Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
RV521 is to being developed to treat RSV infection and disease in susceptible individuals at
high risk for complications. This is an international, multicenter, placebo-controlled study.
Eligible subjects are adults with a documented symptomatic RSV infection who have undergone
HCT transplantation and are moderately to severely immunocompromised. Qualified subjects will
be randomized in a 1:1 ratio to receive RV521 or placebo, twice daily for 10 days.